COMMUNIQUÉS West-GlobeNewswire

Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
02/11/2026
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the [...]
Regeneron Announces Investor Conference Presentations
02/11/2026
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m. GMT [...]
Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors
02/11/2026
Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext [...]
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
02/11/2026
- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/11/2026
WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
02/11/2026
– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute leukemia [...]
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
02/11/2026
– CASGEVY ® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with [...]
CVRx to Participate in Upcoming Investor Conferences
02/11/2026
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Dianthus Therapeutics to Participate in Five Investor Conferences During November
02/11/2026
NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Xenon to Report Q3 2026 Financial Results on November 9, 2026
02/11/2026
VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
Avalo Therapeutics to Participate in Upcoming Investor Conferences
02/11/2026
WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Assembly Biosciences to Participate in Upcoming Investor Conferences
02/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today [...]
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
02/11/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following [...]
Coloplast A/S Announcement no. 11/2026 - 2025/26 Full-Year Financial Results
02/11/2026
1 October 2025 - 30 September 2026 Coloplast delivered 5% organic growth in Q4, driven by continued strength in Chronic Care and Interventional Urology. EBIT growth 1 in constant currencies was 0% and includes negative [...]
Coloplast A/S Announcement no. 10/2026 - Coloplast announces revised financial ambition towards 2030 and FY 2026/27 guidance
02/11/2026
Announcement no. 10/2026 Inside information Revised financial ambition towards 2030 includes 5-7% organic growth per year and an EBIT margin 1 in constant currencies in the mid-20% range over the period. Return on [...]
Z Optics Receives Approval to Expand European Clinical Study of the Z+ Virtual Aperture IOL to Canada
02/11/2026
Following exceptional feedback from patients and physicians in Europe, the clinical trial of the Virtual Aperture intraocular lens will now open to clinical sites and patients in Canada RENO, Nev., Nov. 02, 2026 (GLOBE [...]
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage
02/11/2026
Two Clinical Programs, a 500-Patient Vision, and a November that Could Be a Game-Changer for the Growing Wall Street Story DENVER, Nov. 02, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com ) — In a market where the latest [...]
Quiet Communities Launches Free Science-based Resource Hub to Help Communities Address Data Center Noise
02/11/2026
Downloadable materials translate public health research and acoustical expertise into practical guidance for addressing noise throughout data center planning, construction and operation LINCOLN, Mass., Nov. 02, 2026 ( [...]
Transactions under Novonesis’ share buyback program
02/11/2026
Please read the announcement in PDF Attachment 2026_26_Share_buyback

Pages